ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …

The newly available, urine-based ExoDx Prostate(IntelliScore) test

Back in April this year we reported on the publication of an article in JAMA Oncology that gave information about the development of a new test for risk of clinically significant prostate cancer — a test that could be conducted using a simple urine sample. … READ MORE …

For very high-risk patients, EBRT + BT is superior to surgery or EBRT only

A retrospective analysis of oncological outcomes among modern-era patients with a Gleason score of 9 or 10 demonstrates a clear advantage to a combination of external beam radiation therapy (EBRT) with a brachytherapy (BT) boost to the prostate and short–term androgen deprivation therapy (ADT). … READ MORE …

Early, adjuvant chemotherapy in high-risk patients after surgery

A paper presented yesterday at the now-completed annual meeting of the American Urological Association has given us new data on the role of adjuvant chemotherapy alone in the treatment of men with high-risk prostate cancer. … READ MORE …

Adding radiation increases survival vs. lifelong hormone therapy alone in high-risk men

Long-term follow-up of a Scandinavian randomized clinical trial has confirmed the survival benefit of adding external beam radiation to permanent ADT in high-risk prostate cancer patients. … READ MORE …

Toxicity higher with hypofractionation in Dutch radiotherapy trial using 3D-CRT

A Dutch research group has published the toxicity outcomes of a randomized clinical trial (HYPRO) designed to test whether a hypofractionated external beam (EBRT) regimen compared to conventional fractionation. They will report on the oncological outcomes at a later date. … READ MORE …

Neoadjuvant chemotherapy prior to surgery in higher-risk patients

A combined Russian and German research team has provided some interesting preliminary information on the use of neoadjuvant, low-dose docetaxel-based chemotherapy in treatment of intermediate- and high-risk patients prior to radical prostatectomy. … READ MORE …

Unexpected and perhaps intriguing data from the STAMPEDE trial

In a poster presentation to be given at the upcoming Genitourinary Cancers Symposium in San Francisco later this week, data from the STAMPEDE trial in the UK appear to have demonstrated a result that few people seem to have expected. … READ MORE …

Long-term survival of high-risk patients < 60 years of age treated by radical prostatectomy

A multi-institutional, international study has provided us with data on the 10-, 15-, and 20-year survival of a cohort of 600 relatively young, high-risk prostate cancer patients, all of whom were treated with first-line radical prostatectomy. … READ MORE …

ADT and radiation for first-line treatment of node-positive (N1) prostate cancer (STAMPEDE trial details)

In a previous commentary, we mentioned the early top-line results of the STAMPEDE trial, which demonstrated a benefit to whole pelvic radiation and ADT for treatment of high-risk prostate cancer when positive pelvic lymph nodes have been detected. We now have some additional details. … READ MORE …

Adding ADT to radiation therapy problematic for high-risk patients with history of heart disease

A new research letter just published in the Journal of the American Medical Association appears to confirm the risks associated with use of androgen deprivation therapy (ADT) for treatment of prostate cancer among men with a history of significant heart disease. … READ MORE …

HDRBT monotherapy in treatment of high-risk prostate cancer

Three randomized clinical trials (Sathya et al., 2005; Hoskin et al., 2012; and Guix et al., 2013) established the combination of external beam radiation therapy (EBRT) with a high dose rate brachytherapy (HDRBT) boost as a standard of care in the treatment of high-risk prostate cancer. … READ MORE …

Low serum T and high-risk prostate cancer in Korean men

A group of Korean researchers have poublished data suggesting that — at least in Korean patients — there may be an association between having a low serum testosterone (serum T) level and diagnosis with high-grade prostate cancer. … READ MORE …

Chemo + ADT + RT: no benefit after 10 years

Earlier this month, we looked at the evidence of benefit for adding chemotherapy to androgen deprivation therapy (ADT) + radiation therapy (RT) for high-risk prostate cancer (see “Docetaxel with radiation in prostate cancer treatment”). … READ MORE …

Adding docetaxel to ADT and radiation therapy for high-risk prostate cancer

Earlier today, at the annual meeting of the American Society of Clinical Oncology (ASCO), we were given the results of RTOG 0521 — a large, randomized trial of adding docetaxel chemotherapy to androgen deprivation therapy (ADT) and radiation therapy for men with high-risk prostate cancer. … READ MORE …